Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
7.15
-0.15 (-2.05%)
Aug 13, 2025, 4:00 PM - Market closed
Exicure Revenue
In the year 2024, Exicure had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
45.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | -6,068.12% |
| Dec 31, 2021 | -483.00K | -17.10M | -102.91% |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
XCUR News
- 5 days ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 9 days ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 12 days ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 6 weeks ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 3 months ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
- 4 months ago - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire